Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin(®) Outcomes Registry and Experience (EU-CORE).

Achyut GuleriRiccardo UtiliPascal DohmenNicola PetrosilloCornelia PiperRashidkhan PathanKamal A Hamed

Published in: Infectious diseases and therapy (2015)

Data from this real-world clinical setting showed that daptomycin was well tolerated and effective for the treatment of LIE and BRLIE in addition to RIE caused by Gram-positive bacteria, including MRSA. Two-year follow-up data showed that a high proportion of patients had a sustained response.

Keyphrases

methicillin resistant staphylococcus aureus
end stage renal disease
electronic health record
newly diagnosed
ejection fraction
chronic kidney disease
combination therapy
prognostic factors
skeletal muscle
replacement therapy